Global Cancer Technology (2022)
About this raise
Global Cancer Technology, with a valuation of $26.6 million, is raising funds on NetCapital. The company has acquired multiple patented technologies currently being tested as a novel treatment for deadly diseases. The technology is presently focused on detecting and treating brain cancer and includes scintillating nanoparticles, cancer biomarkers, and cancer inhibitors. Global Cancer Technology is working with world-renowned scientists of the Barrow Neurological Institute, Baylor Scott & White Hospital, and University of California San Diego. John P. Clark founded Global Cancer Technology in May 2017. The current crowdfunding campaign has a minimum target of $10,000 and a maximum target of $1,070,000. The campaign proceeds will be used for research and development, university scientific consulting, and general and administrative costs.
Investment Overview
Not Funded: $0
Deal Terms
Total Commitments
- Platform
- Netcapital
- Start Date
- 02/08/2022
- Close Date
- 04/29/2022
$10,000
$1,070,000
$100
Equity - Common
Early Stage
RegCF
$2.00
$26,682,636
Company & Team
Company
- Year Founded
- 2017
- Industry
- Healthcare & Pharmaceuticals
- Tech Sector
- Distribution Model
- B2B/B2C
- Margin
- Medium
- Capital Intensity
- High
Upgrade to gain access
-
$12.50 /month
billed annually - Free portfolio tracking, data-driven ratings, AI analysis and reports
- Plan Includes:
- Everything in Free, plus
- Company specific
Kingscrowd ratings and analyst reports
- Deal explorer and side-by-side comparison
- Startup exit and failure tracking
- Startup market filters and historical industry data
- Advanced company search ( with ratings)
- Get Edge Annual
Edge
Ratings 
Company Funding & Growth
Funding history
| Close Date | Platform | Valuation | Total Raised | Security Type | Status | Reg Type |
|---|---|---|---|---|---|---|
| 04/29/2022 | Netcapital | $26,682,636 | $0 | Equity - Common | Not Funded | RegCF |
| 09/08/2021 | Dalmore Group | - | $24,400 | Equity - Common | Funded | RegA+ |
| 02/25/2020 | Netcapital | $11,571,400 | $107,000 | Equity - Common | Funded | RegCF |
Growth Charts
Revenue History
Note: Revenue data points reflect the latest of either the most recent fiscal year's financials, or updated revenues directly from the founder, at each raise's close date.
Valuation History
Price per Share History
Note: Share prices shown in earlier rounds may not be indicative of any stock splits.